Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

More about Open Access at the Crick

Authors list

Funda Meric-Bernstam Herbert Hurwitz Kanwal Pratap Singh Raghav Robert R McWilliams Marwan Fakih Ari VanderWalde Charles Swanton Razelle Kurzrock Howard Burris Christopher Sweeney Ron Bose David R Spigel Mary S Beattie Steven Blotner Alyssa Stone Katja Schulze Vaikunth Cuchelkar John Hainsworth
Scroll for detail on labs, facilities & authors

Abstract

Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

Journal details

Journal Lancet Oncology
Volume 20
Issue number 4
Pages 518-530
Available online
Publication date

Full text links

Publisher website (DOI) 10.1016/s1470-2045(18)30904-5
Europe PubMed Central 30857956
Pubmed 30857956

Keywords

Related topics
Type of publication

Related content